Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year...
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes
About this item
Full title
Author / Creator
Bressler, Neil M , Veith, Miroslav , Hamouz, Jan , Ernest, Jan , Zalewski, Dominik , Studnička, Jan , Vajas, Attila , Papp, András , Vogt, Gabor , Luu, James , Matuskova, Veronika , Yoon, Young Hee , Pregun, Tamás , Kim, Taehyung , Shin, Donghoon , Oh, Inkyung , Jeong, Hansol , Kim, Mercy Yeeun and Woo, Se Joon
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
Background/AimsTo provide longer-term data on efficacy, safety, immunogenicity and pharmacokinetics (PK) of ranibizumab biosimilar SB11 compared with the reference ranibizumab (RBZ) in patients with neovascular age-related macular degeneration (nAMD).Methods Setting: Multicentre. Design: Randomised, double-masked, parallel-group, phase III equivale...
Alternative Titles
Full title
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9985746
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9985746
Other Identifiers
ISSN
0007-1161
E-ISSN
1468-2079
DOI
10.1136/bjophthalmol-2021-319637
